Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: Preventive effect of lurasidone treatment during adolescence

Luoni, Alessia; Berry, Alessandra; Calabrese, Francesca; Capoccia, Sara; Bellisario, Veronica; Gass, Peter; Cirulli, Francesca; Riva, Marco A.

doi:10.1016/j.euroneuro.2013.12.010

Cited by 64 publications

(60 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We previously reported that the antipsychotic medication clozapine increased BDNF in rat brain [25]. This observation is replicated in both animals and humans using different antipsychotic medications [26–28]. Further, the current sample consisted of mostly male patients and the BDNF elevating effect of antipsychotic medication could be more robust in male patients[29].…”

Section: Discussionsupporting

confidence: 54%

Is Schizophrenia a Neurodegenerative Disease? Evidence from Age-Related Decline of Brain-Derived Neurotrophic Factor in the Brains of Schizophrenia Patients and Matched Nonpsychiatric Controls

Rao

Chiappelli²,

Kochunov³

et al. 2014

Neurodegener Dis

View full text Add to dashboard Cite

Background: Brain-derived neurotrophic factor (BDNF) protein levels decline in the brain during senescence and are also shown to be reduced in schizophrenia patients. BDNF is present in both the gray and white matters of the brain. It is unclear whether BDNF abnormalities in schizophrenia are specific to gray and/or white matter. Objective: We hypothesized that the age-related BDNF decline is abnormal and contributes to the reduced BDNF in schizophrenia. Methods: We tested this hypothesis by measuring BDNF protein levels in postmortem gray and white matter, using the prefrontal cortex (PFC) and the genu of the corpus callosum as regions of interests, from 20 schizophrenia patients and 20 matched nonpsychiatric controls. Samples were selected across the adult lifespan - from 20 to 80 years of age. Results: PFC gray matter BDNF protein levels were significantly lower in older age in both nonpsychiatric comparisons and patients, while BDNF in white matter did not decrease significantly with age in either group. PFC BDNF was linearly lower from 20 to 80 years of age in nonpsychiatric comparisons. In schizophrenia, the age effect was similarly linear in younger patients but a decline did not occur in older patients. Conclusion: PFC BDNF does not follow a normative linear age effect in schizophrenia patients as they grow older, which may represent a ‘floor effect' due to earlier decline or a survivor cohort of older patient donors who are less susceptible to a schizophrenia-related pathological aging process.

show abstract

Section: Discussionsupporting

confidence: 54%

Is Schizophrenia a Neurodegenerative Disease? Evidence from Age-Related Decline of Brain-Derived Neurotrophic Factor in the Brains of Schizophrenia Patients and Matched Nonpsychiatric Controls

Rao

Chiappelli²,

Kochunov³

et al. 2014

Neurodegener Dis

View full text Add to dashboard Cite

show abstract

“…Antipsychotic drugs, especially upon repeated chronic administration, can also alter the brain levels of BDNF [27, 54, 55] (but see [56]) and prevent the stress-induced decrease in the levels of BDNF [27, 54, 56-59]. One recent study suggests that adolescent treatment of lurasidone prevented the reduction of prefrontal BDNF expression in adult rats that were exposed to prenatal stress [60]. Fourth, it is well established that repeated antipsychotic treatment causes an increase in ΔFosB in several forebrain areas (e.g.…”

Section: Discussionmentioning

confidence: 99%

Asenapine sensitization from adolescence to adulthood and its potential molecular basis

Shu

Qin²,

Chen

et al. 2014

Behavioural Brain Research

View full text Add to dashboard Cite

Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. Brain-derived neurotrophic factor (BDNF), dopamine D2 receptor, and ΔFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20 mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0 mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (∼P 76), asenapine sensitization was assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being injected with asenapine (0.10 mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and ΔFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting. In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20 mg/kg) in adolescence made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous motor activity than those previously treated with saline. However, no group difference in the levels of BDNF, D2 and ΔFosB expression was found. These findings suggest that although adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and ΔFosB.

show abstract

“…Npas4-KO mice also replicate schizophrenia-like behaviors, including social anxiety, hyperactivity, and sensorimotor gating deficits [97]. Notably, repeated treatment with aripiprazole (a partial agonist of the dopamine D2 receptor) upregulates Npas4, indicating that augmentation of Npas4 using novel antipsychotic drugs might improve the cognitive defects of schizophrenia [98,99]. However, caution should be used when interpreting data from animal models of neuropsychiatric disorders given the functional and anatomical differences between human and rodent brains.…”

Section: Dysfunction Of Inhibitory Synaptic Proteins In Brain Diseasesmentioning

confidence: 96%

The balancing act of GABAergic synapse organizers

Choii

2015

Trends in Molecular Medicine

View full text Add to dashboard Cite

Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: Preventive effect of lurasidone treatment during adolescence

Cited by 64 publications

References 56 publications

Is Schizophrenia a Neurodegenerative Disease? Evidence from Age-Related Decline of Brain-Derived Neurotrophic Factor in the Brains of Schizophrenia Patients and Matched Nonpsychiatric Controls

Is Schizophrenia a Neurodegenerative Disease? Evidence from Age-Related Decline of Brain-Derived Neurotrophic Factor in the Brains of Schizophrenia Patients and Matched Nonpsychiatric Controls

Asenapine sensitization from adolescence to adulthood and its potential molecular basis

The balancing act of GABAergic synapse organizers

Contact Info

Product

Resources

About